Personalized management of pheochromocytoma and paraganglioma
S Nölting, N Bechmann, D Taieb… - Endocrine …, 2022 - academic.oup.com
Pheochromocytomas/paragangliomas are characterized by a unique molecular landscape
that allows their assignment to clusters based on underlying genetic alterations. With around …
that allows their assignment to clusters based on underlying genetic alterations. With around …
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working …
JWM Lenders, MN Kerstens, L Amar… - Journal of …, 2020 - journals.lww.com
Phaeochromocytoma and paraganglioma (PPGL) are chromaffin cell tumours that require
timely diagnosis because of their potentially serious cardiovascular and sometimes life …
timely diagnosis because of their potentially serious cardiovascular and sometimes life …
New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification
A molecular biology–based taxonomy has been proposed for pheochromocytoma and
paraganglioma (PPGL). Data from the Cancer Genome Atlas revealed clinically relevant …
paraganglioma (PPGL). Data from the Cancer Genome Atlas revealed clinically relevant …
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants
Patients with germline SDHD pathogenic variants (encoding succinate dehydrogenase
subunit D; ie, paraganglioma 1 syndrome) are predominantly affected by head and neck …
subunit D; ie, paraganglioma 1 syndrome) are predominantly affected by head and neck …
PPAR-α modulators as current and potential cancer treatments
Y Tan, M Wang, K Yang, T Chi, Z Liao, P Wei - Frontiers in oncology, 2021 - frontiersin.org
Cancer is one of the leading causes of mortality worldwide. PPAR modulators may hold
great potential for the management of cancer patients. Indeed, PPARs are critical sensors …
great potential for the management of cancer patients. Indeed, PPARs are critical sensors …
15 Years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1–5
DE Benn, BG Robinson… - Endocrine-related …, 2015 - erc.bioscientifica.com
The paraganglioma (PGL) syndromes types 1–5 are autosomal dominant disorders
characterized by familial predisposition to PGLs, phaeochromocytomas (PCs), renal cell …
characterized by familial predisposition to PGLs, phaeochromocytomas (PCs), renal cell …
Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study
MP Yadav, S Ballal, RK Sahoo, C Bal - European Journal of Nuclear …, 2022 - Springer
Purpose In this study, we aim to evaluate the efficacy and safety of 225 AC-DOTATATE
targeted alpha therapy in advanced-stage paragangliomas (PGLs). Methods Nine (6 males …
targeted alpha therapy in advanced-stage paragangliomas (PGLs). Methods Nine (6 males …
Paragangliomas of the head and neck: an overview from diagnosis to genetics
MD Williams - Head and Neck Pathology, 2017 - Springer
Paragangliomas (PGL) develop from the parasympathetic system in the head and neck (HN)
and arise primarily in four distinct areas: Carotid body, vagal, middle ear, and larynx …
and arise primarily in four distinct areas: Carotid body, vagal, middle ear, and larynx …
68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI
I Janssen, CC Chen, D Taieb, NJ Patronas… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent
studies have already shown excellent results in the localization of sympathetic succinate …
studies have already shown excellent results in the localization of sympathetic succinate …
Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma
A Buffet, L Ben Aim, S Leboulleux, D Drui… - The Journal of …, 2019 - academic.oup.com
Abstract Context Pheochromocytomas and paragangliomas (PPGLs) are characterized by a
strong genetic component, with up to 40% of patients carrying a germline mutation in a …
strong genetic component, with up to 40% of patients carrying a germline mutation in a …